The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: Bringing together basic Scientists and Clinicians in the fight against advanced prostate cancer

Cancer Research

Volumn 58, Issue 13, 1998, Pages 2895-2900

  Naitoh, John ^a   Witte, Owen ^b   Belldegrun, Arie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN;

APOPTOSIS; CANCER GROWTH; CANCER RESEARCH; CANCER THERAPY; CONFERENCE PAPER; CYTOGENETICS; CYTOLOGY; GENE THERAPY; IMMUNOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT PLANNING;

EID: 0032127338     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Shu, H. B., Halpin, D. R., and Goeddel, D. V. Casper is a FADD and caspase-related inducer of apoptosis. Immunity, 6: 751-763, 1997.
2. Vandevoorde, V., Haegeman, G., and Fiers, W. Induced expression of trimerized intracellular domains of the human tumor necrosis factor (TNF) p55 receptor elicits TNF effects. J Cell Biol., 137: 1627-1638, 1997.
3. Sha, W. C., Liou, H. C., Tuomanen, E. I., and Baltimore, D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell, 80: 321-330, 1995.
4. Lee, N., MacDonald, H., Reinhard, C., Halenbeck, R., Roulston, A., Shi, T., and Williams, L. T. Activation of hPAK65 by capase cleavage induces some of the morphological and biochemical changes of apoptosis. Proc. Natl. Acad. Sci. USA, 94: 13642-13647, 1997.
5. Perry, J. E., and Tindall, D. J. Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP. Cancer Res., 57: 1539-1544, 1996.
6. Blok, L. J., Grossmann, M. E., Perry, J. E., and Tindall, D. J. Characterization of an early growth response gene, which encodes a zinc finger transcription factor, potentially involved in cell cycle regulation. Mol. Endocrinol., 9: 1610-1620, 1995.
7. Levin, W. J., Casey, G., Ramos, J. C., Arboleda, M. J., Reissman, P. T., and Slamon, D. J. Tumor suppressor and immediate early transcription factor genes in non-small cell lung cancer. Chest, 106: 372-376, 1994.
8. Gronberg, H., Isaacs, S. D., Smith, J.R., Carpten, J. D., Bova, G. S., Freije, D., Xu, J., Meyers, D. A., Collins, F. S., Trent, J. M., Walsh, P. C., and Isaacs, W. B. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. J. Am. Med. Assoc., 278: 1251-1255, 1997.
9. Eeles, R. A., Dearnaley, D. P., Ardern-Jones, A., Shearer, R. J., Easton, D. F., Ford, D., Edwards, S., and Dowe A. Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. B. J. Urol., 79(Suppl.): 8-14, 1997.
10. Bauer, J. J., Connelly, R. R., Sesterhenn, I. A., Bettencourt, M. C., McLeond, D. G., Srivastava, S., and Moul, JH. W. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer, 79: 952-962, 1997.
11. Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Brufsky, A., Talcott, J., Hennekens, C. H., and Kantoff, P. W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA, 94: 3320-3332, 1997.
12. Choong, C. S., Kemppainen, J. A., Zhou, Z. X., and Wilson, E. M. Reduced and androgen receptor gene expression with first exon CAG repeat expansion. Mol. Endocrinol., 10: 1527-1535, 1996.
13. Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcell, M., Belldegrun, A., Witte, O. N., and Sawyers, C. L. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med., 3: 402-408, 1997.
14. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wanf, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Giovanella, B. C., Ittman, M., Tycko, B., Hishoosh, H., Wigler, M. H., and Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Washington DC), 275: 1943-1947, 1997.
15. Conover, C. A., Perry, J. E., and Tindall, D. J. Endogenous cathepsin D mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin. Endocrinol. Metab., 80: 987-993, 1995.
16. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science (Washington DC), 279: 563-566, 1998.
17. Gingrich, J. R., Barrios, R. J., Morton, R. A., Boyce, B. F., DeMayo F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M., and Greenberg, N. M. Metastatic prostate cancer in a transgenic mouse. Cancer Res., 56: 4096-4102, 1996.
18. Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C., and Greenberg, N. M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res., 57: 3325-3330, 1997.
19. Negrini, M., Monaco, C., Vorchovsky, I., Ohta, M., Druck, T., Baffa, R., Huebner, K., and Croce, C. M. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res., 56: 3173-3179, 1996.
20. Siprashvili, Z., Sozzi, G., Bames, L. D., McCue, P., Robinson, A. K., Eryomin, V., Sard, L., Tagliabue, E., Greco, A., Fusetti, L., Schwartz, G., Pierotti, M. A., Croce, C. M., and Huebner, K. Replacement of FHIT in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. USA, 94: 13771-13776, 1997.
21. Oberneder, R., Riesenberg, R., Kriegmair, M., Mitzer, U., Klammert, R., Schneede, P., Hofstetter, A., Riethmuller, and Pantel, K. Immunocytochemical detection and phenotypic characterization of micrometastatic tumor cells in bone marrow of patients with prostate cancer. Urol. Res., 22: 3-8, 1994.
22. Petrasch, S., and Schmiegel, W. Adjuvant therapy of colon carcinoma: results of two intergroup studies (INT-0035 and INT-0089), a study by the German Cancer Aid 17-1A Study Group and the IMPACT study. Z. Gastroenterol., 35: 49-52, 1997.
23. Casillas, S., Pelley, R. J., and Milsom, J. W. Adjuvant therapy for colorectal cancer: present and future perspectives. Dis. Colon Rectum, 40: 977-992, 1997.
24. Koivisto, P., Hyytinen, E., Palmberg, C., Tammela, T., Visakorpi, T., Isola, J., and Kallioniemi, O. P. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am. J. Pathol., 147: 1608-1614, 1995.
25. Koivisto, P., Visakorpi, T., and Kallioniemi, O. P. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand. J. Clin. Lab. Invest. Suppl., 226: 57-63, 1996.
26. Koivisto, P., Kolmer, M., Visakorpi, T., and Kallioniemi, O. P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol., 152: 1-9, 1998.
27. Liu, A. Y., Corey, E., Vessella, R. L., Lange, P. H., True, L. D., Huang, G. M., Nelson, P. S., and Hood, L. Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate, 30: 145-153, 1997.
28. Finn, O. J., Jerome, K. R., Henderson, R. A., Pecher, G., Domenech, N., Magarian-Blander, J., and Barratt-Boyes, S. M. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev., 145: 61-89, 1995.
29. Bohm, C. M., Mulder, M. C., Zennadi, R., Notter, M., Schmitt-Graff, A., Finn, O. J., Taylor-Papadimitriou, J., Stein, H., Clausen, H., Riecken, E. O., et al. Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. Scand. J. Immunol., 46: 27-34, 1997.
30. Jerome, K. R., Kirk, A. D., Pecher, G., Ferguson, W. W., and Finn, O. J. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol. Immunother. 43: 355-360, 1997.
31. Henderson, R. A., Nimgaonkar, M. T., Watkins, S. C., Robbins, P. D., Ball, E. D., and Finn, O. J. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res., 56: 3763-3770, 1996.
32. Mumberg, D., Wick, M., and Schreiber, H. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin. Immunol., 8: 289-293, 1996.
33. Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V., Knudsen, B., and Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res., 57: 3629-3634, 1997.
34. Bander, N. H. Current status of monoclonal antibodies for imaging and therapy of prostate cancer. Semin. Oncol., 21: 607-612, 1994.
35. Liu, K. J., Chatta, G. S., Twardzik, D. R., Vedvick, T. S., True, L. D., Spies, A. G., and Cheever, M. A. Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. J. Immunol. 159: 472-480, 1997.
36. Naitoh, J., and Belldegrun, A. Gene therapy: the future is here. A guide for the practicing urologist. Urology, in press, 1998.
37. Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H., and Verma, I. M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17: 314-317, 1997.
38. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (Washington DC), 272: 263-267, 1996.
39. Blomer, U., Naldini, L., Verma, I. M., Trono, D., and Gage, F. H. Applications of gene therapy to the CNS. Hum. Mol. Genet., 5: 1397-1404, 1996.
40. Wang, L., Zoppe, M., Hackeng, T. M., Griffin, J. H., Lee, K. F., and Verma, I. M. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc. Natl. Acad. Sci. USA, 94: 11563-11566, 1997.
41. Pang, S., Taneja, S., Dardashti, K., et al. Prostate tissue specificity of the prostate specific antigen promoter isolated from a patient with prostate cancer. Hum. Gene Ther., 6: 1417, 1995.
42. Cheng, L., Nagabhushan, M., Pretlow, T. P., Amini, S. B., and Pretlow, T. G. Expression of E-cadherin in primary and metastatic prostate cancer. Am. J. Pathol., 148: 1375-1380, 1996.
43. Shimazui, T., Giroldi, L. A., Bringuier, P. P., Ooserwijk, E., and Schalken, J. A. Complex cadherin expression in renal cell carcinoma. Cancer Res., 56: 3234-3237, 1996.
44. Liu, J., Oh, P., Horner, T., Rogers, R. A., and Schnitzer, J. E. Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J. Biol. Chem. 272: 7211-7222, 1997.
45. Small, E. J., Baron, A., and Bok, R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer (Phila.), 80: 1755-1759, 1997.
46. Pienta, K. J., and Smith, D. C. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin. Oncol., 24: 1572-1577, 1997.
47. Colleoni, M., Graiff, C., Vicario, G., Nelli, P., Sgarbossa, G., Pancheri, F., and Manente, P. Phase II study of estramustine, oral etoposide and vinorelbine in hormone refractory prostate cancer. Am. J. Clin. Oncol. 20: 383-386, 1997.
48. Gibbs, J. B., Kohl, N. E., Koblan, K. S., Omer, C. A., Sepp-Lorenzino, L., Rosen, N., Anthony, N. J., Conner, M. W., deSolms, S. J., Williams, T. M., Graham, S. L., Hartman, G. D., and Oliff, A. Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res. Treat., 38: 75-83, 1996.